Through our commitment to patients suffering from devastating diseases, MyMD is developing a platform of potential products based on our proprietary small molecule.
MyMD’s early stage development program emphasizes collaboration with a team of highly experienced professionals and partner companies. We believe that our collaborative strategy supports cost-effective potential product innovation and accelerated drug development.
The company has developed a proprietary small molecule, which modifies the pathologic effects of Reactive Oxygen Species through regulation of Hydrogen Peroxide. Recent scientific findings have implicated a strong relationship between ROS accumulation and the initiation and progression of autoimmunity.
We are advancing rapidly toward the filing of an Investigational New Drug Application with the FDA for our lead candidate. At the same time, we are developing preclinical programs in other conditions. Our approach could revolutionize treatment for other autoimmune disorders where the underlying pathology also may be driven or enhanced by ROS . These disorders often have a high unmet need for safe, effective therapies.
Di Dalmazi G1,2, Hirshberg J3, Lyle D3, Freij JB4, Caturegli P5,6. Auto Immun Highlights.2016 Dec;7(1):11. doi: 10.1007/s13317-016-0083-0.